

Internalization Booster for Radiolabels to Image and Treat Neuroendocrine Tumors

Use of inhibitors of an intracellular pathway increases the accumulation of radiolabels and can improve theranostics in neuroendocrine tumor



Request an introduction

Reference: IDF 19-21

Source: LASZLO, <https://stock.adobe.com/uk/495861872,stock.adobe.com>

IP Status

Provisional patent

Seeking

Licensing, Development partner

For more information, please contact:

Jonas Pollard
+41 (0)79 556 20 60
jonas.pollard@chuv.ch

Background

One of the greatest challenge with neuroendocrine tumors is to assess the presence of metastases and find efficient therapies since current treatments have been proven to be suboptimal in terms of outcome. The present invention addresses these issues by increasing the accumulation of a radiopharmaceutical used to image or treat certain types of such tumors.

Tech Overview

Researchers have found that specific molecules that inhibit an intracellular pathway yielded an increased uptake of the radiopharmaceutical. This discovery has the potential to improve diagnostic sensitivity and therapeutic efficacy.

Stage of Development

Technology Readiness Level (TRL): 4

- In-vitro study with imaging radiopharmaceutical
- In-vitro study with therapeutic radiopharmaceutical
- Xenografted mice model PoC study

Benefits

- Internalization of radiolabels increased > x2
 - Improved tumor-to-background image contrast
 - Higher dose of radioactivity delivered to the tumor
 - Lower dose of radioactivity in healthy tissue (better specificity)
 - Treatment becomes safer without compromising therapeutic efficacy

Applications

- Diagnosis/Imaging of patients affected by malignant neuroendocrine tumors
- Therapy for patients affected by malignant neuroendocrine tumors

Opportunity

PACTT offers to grant exclusive or non-exclusive license to industrial partners able to develop and commercialize the technology.

Learn more about this opportunity

About IN-PART

Scientific collaborations should solve real-world problems and bring a positive impact to society. That's why we facilitate and accelerate the bench-to-bedside journey by connecting the right partners from industry and academia.

Connect is an online matchmaking platform subscribed to by **250+ universities and research institutes** to connect with industry teams in **6,000+ companies** to commercialise academic innovations and expertise that are available and seeking collaboration. [Create your free Connect account!](#)